Gabapentin 1800mg/day Safe, Effective for PHN, Says Study
the MPR take:
In a recent study published in the Journal of Clinical Pharmacy and Therapeutics, the use of 1800mg/day of gabapentin was found to significantly reduce pain associated with post-herpetic neuralgia (PHN) up to 14 weeks; treatment also appeared to be safe up to 24 weeks. The study compared gabapentin 1800mg/day to placebo with primary outcomes being reduction in 24-hour average pain intensity scores, pain intensity reductions of 50% and 30%, and associated adverse effects of therapy. Six randomized controlled trials were included in the analysis which showed that 1800mg/day of gabapentin reduced 24-hour average pain intensity scores and yielded an improvement in pain intensity. While somnolence, dizziness, and peripheral edema did occur, adverse effects of therapy were generally mild to moderate.